Supplemental material
Leukemia & Lymphoma
Volume 65, 2024 - Issue 5
Review Articles
Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations
Naveen Pemmarajua The University of Texas MD Anderson Cancer Center, Houston, Texas, USACorrespondence[email protected]
https://orcid.org/0000-0002-1670-6513View further author information
https://orcid.org/0000-0002-1670-6513View further author information, Yazan F. Madanatb UT Southwestern Medical Center, Dallas, Texas, USAhttps://orcid.org/0000-0001-9573-2690View further author information
https://orcid.org/0000-0001-9573-2690View further author information, David Rizzieric Novant Health Cancer Institute, Winston Salem, North Carolina, USAhttps://orcid.org/0000-0001-9886-5771View further author information
https://orcid.org/0000-0001-9886-5771View further author information, , Raajit Rampale Memorial Sloan Kettering Cancer Center, New York, New York, USAhttps://orcid.org/0000-0002-0355-6368View further author information
https://orcid.org/0000-0002-0355-6368View further author information, , Eunice S. Wangg Roswell Park Comprehensive Cancer Center, Buffalo, New York, USAhttps://orcid.org/0000-0002-8644-0968View further author information
https://orcid.org/0000-0002-8644-0968View further author information, James Foranh Mayo Clinic Cancer Center, Jacksonville, Florida, USAhttps://orcid.org/0000-0003-1673-1708View further author information
https://orcid.org/0000-0003-1673-1708View further author information & Andrew A. Lanei Dana-Farber Cancer Institute, Boston, Massachusetts, USAhttps://orcid.org/0000-0001-7380-0226View further author information
https://orcid.org/0000-0001-7380-0226View further author information show all